OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
September 02, 2012
The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
August 02, 2012
Budgets for biopharmaceutical activities are gaining in select functional areas except outsourcing.
August 01, 2012
The author provides results and commentary on a survey analyzing outsourcing strategies, practices, challenges, and outcomes in the selection of a CRO.
An examination of the current and projected market for biosimilars, development costs for biosimilars compared with small-molecule generic drug, and partnerships in biosimilars.
The author discusses how a CDMO helps in gaining process understanding and in developing robust, high-quality products and processes.
The authors highlight costs, benefits, and implementation success factors across first, second, and third generations of facility management outsourcing contracts.
AMRI, a contract research and manufacturing organization, discusses its adaption of an insourcing model with Eli Lilly.
Annual survey shows strong growth for service providers and promises to continue into 2013.
July 02, 2012
Jim Miller, president of PharmSource, examines the future direction of CROs/CMOs and the factors influencing the pharmaceutical contract services sectors.
The past three decades have driven a purchasing evolution to a procurement revolution.